

11/08/200409:44Print selected from Online session

22 FILE DRUGU  
136 FILE EMBASE  
35 FILES SEARCHED...  
52 FILE ESBIODBASE  
1 FILE FEDRIP  
2 FILE FROSTI  
7 FILE FSTA  
1 FILE GENBANK  
9 FILE IFIPAT  
16 FILE JICST-EPLUS  
24 FILE LIFESCI  
152 FILE MEDLINE  
2 FILE OCEAN  
44 FILE PASCAL  
4 FILE PHIN  
5 FILE PROMT  
1 FILE RDISCLOSURE  
115 FILE SCISEARCH  
67 FILE TOXCENTER  
575 FILE USPATFULL  
36 FILE USPAT2  
2 FILE VETU  
1 FILE WATER  
9 FILE WPIDS  
9 FILE WPINDEX  
1 FILE CASREACT  
77 FILES SEARCHED...  
155 FILE EUROPATFULL  
2 FILE FRFULL  
1 FILE INPADO  
38 FILE PATDPAFULL  
401 FILE PCTFULL

45 FILES HAVE ONE OR MORE ANSWERS, 96 FILES SEARCHED IN STNINDEX

L2 QUE (DHA OR DOCOSAHEXAENOIC) AND ALBUMIN

=> file medline biosis caplus  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
7.41	7.62

FILE 'MEDLINE' ENTERED AT 09:26:20 ON 11 AUG 2004

FILE 'BIOSIS' ENTERED AT 09:26:20 ON 11 AUG 2004  
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'CAPLUS' ENTERED AT 09:26:20 ON 11 AUG 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> DHA or docosahehexaenoic same albumin  
L3 13884 DHA OR DOCOSAHEXAENOIC SAME ALBUMIN

=> docosahehexaenoic same albumin  
L4 0 DOCOSAHEXAENOIC SAME ALBUMIN

=> DHA same albumin

11/08/200409:44Print selected from Online session

FILE 'HOME' ENTERED AT 09:18:26 ON 11 AUG 2004

=> Index Bioscience patents

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

FILE 'ENCOMPPAT' ACCESS NOT AUTHORIZED

FILE 'ENCOMPPAT2' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, AQUALINE, ANABSTR, ANTE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DISSABS, DDFB, DDFU, DGENE, ...' ENTERED AT 09:18:45 ON 11 AUG 2004

96 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0\* with SET DETAIL OFF.

=> "docosahexaenoic acid" same albumin

17 FILES SEARCHED...

28 FILES SEARCHED...

39 FILES SEARCHED...

56 FILES SEARCHED...

72 FILES SEARCHED...

79 FILES SEARCHED...

93 FILES SEARCHED...

0 FILES HAVE ONE OR MORE ANSWERS, 96 FILES SEARCHED IN STNINDEX

L1 QUE "DOCOSAHEXAENOIC ACID" SAME ALBUMIN

=> ("docosahexaenoic acid" or DHA or docosahexaenoic) same albumin

MISSING OPERATOR SAME

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> (DHA or docosahexaenoic) same albumin

MISSING OPERATOR SAME

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> (DHA or docosahexaenoic) and albumin

4	FILE ADISCTI
12	FILE AGRICOLA
1	FILE ANABSTR
2	FILE AQUASCI
2	FILE BIOENG
151	FILE BIOSIS
3	FILE BIOTECHABS
3	FILE BIOTECHDS
33	FILE BIOTECHNO
43	FILE CABA
38	FILE CANCERLIT
166	FILE CAPLUS
1	FILE CEABA-VTB
10	FILE DISSABS
12	FILE DDFU

L5 0 DHA SAME ALBUMIN

=> DHA adj15 albumin

L6 0 DHA ADJ15 ALBUMIN

=> DHA and albumin

L7 247 DHA AND ALBUMIN

=> docosahexaenoic and albumin

L8 363 DOCOSAHEXAENOIC AND ALBUMIN

=> "docosahexaenoic acid" and albumin

L9 343 "DOCOSAHEXAENOIC ACID" AND ALBUMIN

=> "docosahexaenoic acid" (p) albumin

L10 258 "DOCOSAHEXAENOIC ACID" (P) ALBUMIN

=> dupilcate remove

L11 0 DUPLICcate REMOVE

=> "docosahexaenoic acid" (p) albumin and " pharmaceutical composition"

L12 1 "DOCOSAHEXAENOIC ACID" (P) ALBUMIN AND " PHARMACEUTICAL COMPOSIT  
ION"

=> d ti 1

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN

TI Docosahexaenoates for inhibition of blood platelet-activating factor (PAF)  
production

=> d ab bib 1

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN

AB Docosahexaenoates are useful for inhibition of PAF production, i.e. useful for  
treatment of asthma and other inflammatory and allergic diseases. Human  
leukemia Eol-1 cells were cultured in RPMI-1640 medium containing  
interferon- $\gamma$  and bovine fetal serum for 3 days, cultured in the  
presence of 10  $\mu$ M **docosahexaenoic acid** (I) for 1  
day, and treated with MEM medium containing bovine serum **albumin** and  
20  $\mu$ M Ca ionophore A23187 at 37° for 5 min to show 39.65  
pmol/107 cells PAF production, vs. 85.28 pmol/107 cells, for the controls.  
Gelatin soft capsules containing 99.7 weight% I and 0.3 weight%  $\alpha$ -tocopherol  
were formulated.

AN 1993:463051 CAPLUS

DN 119:63051

TI Docosahexaenoates for inhibition of blood platelet-activating factor (PAF)  
production

IN Yazawa, Kazuyoshi; Masuzawa, Yasuo; Kano, Mayumi

PA Sagami Chem Res, Japan

SO Jpn. Kokai Tokkyo Koho, 3 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 05043456	A2	19930223	JP 1991-226338	19910813
PRAI	JP 1991-226338		19910813		

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	65.86	73.48

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.74	-0.74

FILE 'STNGUIDE' ENTERED AT 09:32:00 ON 11 AUG 2004  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Aug 6, 2004 (20040806/UP).

=> "docosahexaenoic acid" (p) albumin and conjugated

```
0 "DOCOSAHEXAENOIC"
6 "ACID"
1 "ACIDS"
6 "ACID"
  ("ACID" OR "ACIDS")
0 "DOCOSAHEXAENOIC ACID"
  ("DOCOSAHEXAENOIC" (W) "ACID")
0 ALBUMIN
0 "DOCOSAHEXAENOIC ACID" (P) ALBUMIN
0 CONJUGATED
L13 0 "DOCOSAHEXAENOIC ACID" (P) ALBUMIN AND CONJUGATED
```

=> ("docosahexaenoic acid" (p) albumin) and conjugated

```
0 "DOCOSAHEXAENOIC"
6 "ACID"
1 "ACIDS"
6 "ACID"
  ("ACID" OR "ACIDS")
0 "DOCOSAHEXAENOIC ACID"
  ("DOCOSAHEXAENOIC" (W) "ACID")
0 ALBUMIN
0 "DOCOSAHEXAENOIC ACID" (P) ALBUMIN
0 CONJUGATED
L14 0 ("DOCOSAHEXAENOIC ACID" (P) ALBUMIN) AND CONJUGATED
```

=> ("docosahexaenoic acid" (p) albumin) and composition

```
0 "DOCOSAHEXAENOIC"
6 "ACID"
1 "ACIDS"
6 "ACID"
  ("ACID" OR "ACIDS")
0 "DOCOSAHEXAENOIC ACID"
  ("DOCOSAHEXAENOIC" (W) "ACID")
0 ALBUMIN
0 "DOCOSAHEXAENOIC ACID" (P) ALBUMIN
16 COMPOSITION
  1 COMPOSITIONS
16 COMPOSITION
  (COMPOSITION OR COMPOSITIONS)
```

11/08/200409:44Print selected from Online session

L19            0 "DOCOSAHEXAENOIC ACID" (P)    ALBUMIN

=> file biosis medline caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.48	73.96

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.74

FILE 'BIOSIS' ENTERED AT 09:36:56 ON 11 AUG 2004  
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 09:36:56 ON 11 AUG 2004

FILE 'CAPLUS' ENTERED AT 09:36:56 ON 11 AUG 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> "docosahexaenoic acid" (p)    albumin  
L20            258 "DOCOSAHEXAENOIC ACID" (P) ALBUMIN

=> ("docosahexaenoic acid" (p)    albumin) and composition  
L21            48 ("DOCOSAHEXAENOIC ACID" (P) ALBUMIN) AND COMPOSITION

=> ("docosahexaenoic acid" (p)    albumin) and composition and conjugated  
L22            0 ("DOCOSAHEXAENOIC ACID" (P) ALBUMIN) AND COMPOSITION AND CONJUGA  
                     TED

=> ("docosahexaenoic acid" (p)    albumin) and composition and bound  
L23            7 ("DOCOSAHEXAENOIC ACID" (P) ALBUMIN) AND COMPOSITION AND BOUND

=> d ti 1-7

L23    ANSWER 1 OF 7    BIOSIS    COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
TI    INHIBITION OF APOLIPOPROTEIN SECRETION AND PHOSPHATIDATE PHOSPHOHYDROLASE  
      ACTIVITY BY EICOSAPENTAENOIC AND DOCOSAHEXAENOIC ACIDS IN THE PERFUSED RAT  
      LIVER.

L23    ANSWER 2 OF 7    BIOSIS    COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
TI    FATTY ACIDS **BOUND** TO ALPHA FETOPROTEIN AND ALBUMIN DURING RAT  
      DEVELOPMENT.

L23    ANSWER 3 OF 7            MEDLINE on STN  
TI    Inhibition of apolipoprotein secretion and phosphatidate phosphohydrolase  
      activity by eicosapentaenoic and docosahexaenoic acids in the perfused rat  
      liver.

L23    ANSWER 4 OF 7            MEDLINE on STN  
TI    Fatty acids **bound** to alpha-fetoprotein and albumin during rat  
      development.

L23    ANSWER 5 OF 7    CAPLUS    COPYRIGHT 2004 ACS on STN  
TI    Inhibition of apolipoprotein secretion and phosphatidate phosphohydrolase  
      activity by eicosapentaenoic and docosahexaenoic acids in the perfused rat  
      liver

L23 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN

TI Fatty acids **bound** to  $\alpha$ -fetoprotein and albumin during rat development

L23 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN

TI Long-chain acyl-coenzyme A synthetase from rat brain microsomes. Kinetic studies using [1-<sup>14</sup>C]docosahexaenoic acid substrate

=> d ab bib 1,2,

L23 ANSWER 1 OF 7 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

AB Infusion of **albumin-bound** eicosapentaenoic acid (EPA) **docosahexaenoic acid** (DHA), or oleic acid (OA) in perfused rat livers was carried out for two hours at a rate that maintained the perfusate concentration at 1 mmol/L. When compared with fatty acid-poor **albumin** alone, triacylglycerol (TAG) output was not significantly increased with DHA or EPA, whereas OA infusion resulted in a twofold increase. Incorporation of labeled leucine into VLDL apo B-100, apo B-48, apo E, and apo Cs was decreased by 50% by DHA or EPA compared with OA. The total phosphatidate phosphohydrolase activity was decreased by 35% with DHA or EPA compared to oleic acid or **albumin** alone. In no case was there a significant change in the distribution of activity between the microsomal and cytosolic fractions. Fatty acid infusion did not significantly change the liver TAG content. Total liver lipids, microsomal lipids, and lipids of secreted VLDL were enriched with the infused fatty acids. The degree of enrichment for secreted TAG averaged 24% for OA and 36% for DHA or EPA. The effects of DHA and EPA on PPH activity and on apo B secretion in feeding experiments with marine oils rich in these acids may relate to changes in the fatty acid **composition** of liver membranes.

AN 1989:74490 BIOSIS

DN PREV198987038888; BA87:38888

TI INHIBITION OF APOLIPOPROTEIN SECRETION AND PHOSPHATIDATE PHOSPHOHYDROLASE ACTIVITY BY EICOSAPENTAENOIC AND DOCOSAHEXAENOIC ACIDS IN THE PERFUSED RAT LIVER.

AU WONG S H [Reprint author]; MARSH J B

CS DEP PHYSIOL BIOCHEM, MED COLL PA, PHILADELPHIA, PA 19129, USA

SO Metabolism Clinical and Experimental, (1988) Vol. 37, No. 12, pp. 1177-1181.

CODEN: META AJ. ISSN: 0026-0495.

DT Article

FS BA

LA ENGLISH

ED Entered STN: 23 Jan 1989

Last Updated on STN: 23 Jan 1989

L23 ANSWER 2 OF 7 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

AB The time-course levels and **composition** of the fatty acids **bound** to rat  $\alpha$ -fetoprotein (AFP) and **albumin** from several sources, were determined throughout development, and related to the intake of lipids from milk and the compositional changes in brain and liver fatty acids. The major fatty acids **bound** to AFP were polyunsaturated and mainly **docosahexaenoic acid** (22:6(n - 3)), either from fetal serum (23.1%) or whole fetuses (21.6%), whereas palmitic (34.1%) and oleic (29.9%) acids were the main acids **bound** to **albumin** from the same sources. Amniotic fluid AFP contained less fatty acids (0.8 mol/mol protein) than that of fetal serum (1.4 mol/mol protein), and especially noticeable was a reduced

amount of 22:6 (9.6%). Both AFP-concanavalin A microforms showed identical fatty acid **composition**. Levels of 22:6 **bound** to AFP decreased quickly after birth until a minimum at 8-10 days, increasing moderately thereafter. This minimum is coincident in time with a maximal accumulation of this fatty acid by brain and a loss of 22:6 by liver. Except for colostrum, levels of 22:6 in milk lipids were low and fairly constant, but always greater than those of its precursor, linolenic acid (18:3 (n - 3)). These results support a specialized role of AFP in the plasma transport and tissue delivery of polyunsaturated fatty acids, and mainly **docosahexaenoic acid**.

AN 1988:284784 BIOSIS  
DN PREV198886013051; BA86:13051  
TI FATTY ACIDS **BOUND** TO ALPHA FETOPROTEIN AND ALBUMIN DURING RAT DEVELOPMENT.  
AU CALVO M [Reprint author]; NAVAL J; LAMPREAVE F; URIEL J; PINEIRO A  
CS DEP TECNOL BIOQUIM ALIMENTOS, FAC VET, UNIV ZARAGOZA, MIGUEL SERVET 177, 50013 ZARAGOZA, SPAIN  
SO Biochimica et Biophysica Acta, (1988) Vol. 959, No. 3, pp. 238-246. CODEN: BBACAQ. ISSN: 0006-3002.  
DT Article  
FS BA  
LA ENGLISH  
ED Entered STN: 16 Jun 1988  
Last Updated on STN: 16 Jun 1988